ClinicalTrials.gg
RecruitingNCT07773051Updated Aug 19, 2026

LineMatrix® Biological Vascular Graft for the Creation of Arteriovenous Graft

An interventional study of LineMatrix® Biological Vascular Graft and GORE-INTERING® in Arteriovenous Graft, sponsored by Longhua Hospital. Recruiting at 12 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Longhua Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Aug 2025, registered Aug 2026).
  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
326
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Kidney Failure, Chronic with a site in China — 28 open to participants now, 36 under way, 1 of them phase 3. Kidney Failure, Chronic · China.

Planned enrollment
23rd of 83
326 · median 150
Started
2025
with 11 others
No phase
40 of 114
9 open now
Primary completion
2027-06
later than 24 of 35 live
Registered
112th of 114
by date

Among the 114 studies in Kidney Failure, Chronic with a site in China, this one is the 23rd largest by planned enrollment of the 83 interventional ones that give a count, is one of 12 that started in 2025, is one of 40 with no phase, reaches primary completion later than 24 of the 35 other live ones, and was the 112th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

28 of the 114 studies in Kidney Failure, Chronic with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Kidney Failure, Chronic with a site in China, or all of them as a file.
02

Study summary

The study is planned to be conducted at multiple centers, with an intended enrollment of 326 subjects. Protocol-eligible subjects will be randomized in a 1:1 ratio to either the investigational group or the control group. The investigational group will receive a Biological Vascular Graft(LineMatrix®) manufactured by Humatrix Medical Technology (Suzhou) Co., LTD, while the control group will receive an arteriovenous graft (GORE-INTERING®) manufactured by W.L. Gore \& Associates, Inc. The primary endpoints are the Primary patency rate at 6 months postoperatively and the Cumulative Patency Rate at 12 Months postoperatively. Subjects will undergo follow-up during the screening period, at the time of AVG procedure, and at 1 month, 3 months, 6 months, and 12 months post-operatively. Safety and efficacy parameters will be observed and recorded during and after the surgery to evaluate the safety and effectiveness of the LineMatrix® Biological Vascular Graft for the creation of arteriovenous graft in patients with end-stage renal disease (ESRD).

03

Conditions studied

  • Arteriovenous Graft

Keywords

  • Arteriovenous Graft
  • Hemodialylsis
  • End Stage Kidney Disease(ESKD)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) Age ≥18 years and ≤80 years, male or female;
  • (2) Diagnosed with end-stage renal disease (ESRD) requiring maintenance hemodialysis;
  • (3) Requiring establishment of a long-term hemodialysis vascular access but unable to have a autologous arteriovenous fistula (AVF) created;
  • (4) Assessed by the investigator as suitable for implantation of an arteriovenous graft (AVG) in the upper extremity;
  • (5) Able to understand the purpose of the study, voluntarily participating and providing signed (ICF), and willing to comply with all scheduled follow-up assessments.

Exclusion criteria

Exclusion Criteria:

  • (1) Known or suspected history of allergy to heparin, alcohol, or bovine-derived products;
  • (2) Planned to undergo renal transplantation or transition to peritoneal dialysis within 1 year;
  • (3) concentration \<60 g/L, or count \<60 × 10⁹/L;
  • (4) (LVEF) \<30%;
  • (5) Severe cardiac disease, including (NYHA) Class III-IV severe heart failure, or history of myocardial infarction, unstable angina, or sustained ventricular tachyarrhythmia requiring continuous treatment within 6 months prior to enrollment;
  • (6) History of stroke within 1 month prior to enrollment;
  • (7) Uncontrolled or poorly controlled diabetes mellitus (preoperative >10%);
  • (8) Immunodeficiency disorders, or current treatment with (prednisone-equivalent dose ≥10 mg) or agents (e.g., sirolimus, mycophenolate mofetil, cyclosporine, cyclophosphamide, tacrolimus);
  • (9) or other severe systemic disease with a of \<12 months;
  • (10) Heparin-induced thrombocytopenia type II (HIT-2) or other to heparin use;
  • (11) (AST) or alanine aminotransferase (ALT) >2 × (ULN);
  • (12) Coagulation disorders ( [APTT] or prothrombin time [PT] >1.5 × ULN);
  • (13) Systemic or surgical site infection (white blood cell [WBC] count >15 × 10⁹/L);
  • (14) Baseline hypotension, or frequent hypotensive episodes within the past month (frequency ≥5 episodes/month, with hypotension defined as systolic blood pressure \<90 mmHg or diastolic blood pressure \<60 mmHg);
  • (15) Hypercoagulable state, or history of ≥2 episodes of deep vein thrombosis or peripheral vascular thrombosis not related to dialysis access;
  • (16) Known ipsilateral central venous stenosis, or clinical symptoms/signs suggestive of central venous stenosis confirmed by imaging;
  • (17) Severe mental disorders that preclude cooperation with the study protocol;
  • (18) Pregnant or lactating women, or women of who plan to conceive during the trial and are unwilling to use effective ;
  • (19) Currently enrolled in another drug or medical device clinical trial and not yet completed the study;
  • (20) Any other conditions that, in the investigator's opinion, make the patient unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
326 participants (estimated)

Study arms

  • Experimental
    LineMatrix® Biological vascular graft

    Device: LineMatrix® Biological Vascular Graft

  • Active comparator
    GORE-INTERING®

    Device: GORE-INTERING®

Interventions

  • DeviceLineMatrix® Biological Vascular Graft

    LineMatrix® Biological Vascular Graft

  • DeviceGORE-INTERING®

    GORE-INTERING®

06

What researchers measure

Primary outcomes

  1. Primary patency rate at 6 months postoperatively

    Primary Patency Rate is defined as the proportion of subjects who have not experienced any of the following events from the date of vascular access creation through 6 months post-operatively: thrombosis, or any intervention performed to promote, maintain, or re-establish patency (e.g., angioplasty).

    Time frame: 6 months

  2. Cumulative Patency Rate at 12 Months Postoperatively

    Cumulative Patency Rate is defined as the proportion of subjects whose vascular access has not been abandoned from the date of vascular access creation through 12 months post-operatively.

    Time frame: 12 months

Secondary outcomes

  1. Primary patency rate at 3,12 months postoperatively

    Primary Patency Rate is defined as the proportion of subjects who have not experienced any of the following events from the date of vascular access creation through 3,12 months post-operatively: thrombosis, or any intervention performed to promote, maintain, or re-establish patency (e.g., angioplasty).

    Time frame: 3,12 months

  2. Cumulative Patency Rate at 3,6 Months Postoperatively

    Cumulative Patency Rate is defined as the proportion of subjects whose vascular access has not been abandoned from the date of vascular access creation through 3, 6 months post-operatively.

    Time frame: 3,6 months

  3. Surgical success rate

    Surgical success rate is defined as the successful completion of the arteriovenous graft (AVG) surgery using the investigational device, without any device-related serious adverse events occurring during the perioperative period.

    Time frame: 30 days

  4. Time to First Cannulation

    Time to First Cannulation is defined as the interval from the AVG procedure to the first hemodialysis session performed using the arteriovenous graft.

    Time frame: 12 months

  5. Device Performance Evaluation

    I.Suturability Excellent: Needle passes through vessel with light touch and no deformation after arterial suturing; Good: Needle passes through vessel with light force and shows deformation after arterial suturing but can continue to be used; Poor: Needle passes through vessel with force and shows severe deformation after arterial suturing and cannot continue to be used. II.Anastomotic bleeding No: No visible blood leakage at anastomosis; Yes: Visible blood leakage at anastomosis. III.Post-cannulation hemostasis Excellent: After removal of the puncture needle, apply manual compression to achieve hemostasis; time to hemostasis is \<10 min. Good: After removal of the puncture needle, apply manual compression to achieve hemostasis; time to hemostasis is 10-15 min. Poor: After removal of the puncture needle, apply manual compression to achieve hemostasis; time to hemostasis is \>15 min, or additional hemostatic measures are required.

    Time frame: 12 months

07

Study locations

12 of 12 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 22 months is close to that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2026
First posted
Aug 19, 2026
StartActual
Aug 25, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07773051
Lead sponsor
Longhua Hospital
Collaborators
Humatrix Medical Technology (Suzhou) Co., LTD
Responsible party
Yaxue Shi (MD, Longhua Hospital) — Principal investigator
First posted
Aug 19, 2026
Start date
Aug 25, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Aug 19, 2026

Study contacts

Xuefeng Qiu
Contact
xuefeng_qiu@humatrix-medical.com
+8613507192551
Yaxue Shi
principal investigator · Longhua Hospital
Hua Li
principal investigator · Sir Run Run Shaw Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion